Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to $380,304.

  • Immuneering's Change in Accured Expenses fell 80.46% to $380,304 in Q4 2024 from the same period last year, while for Dec 2024 it was -$200,831, marking a year-over-year decrease of 127.82%. This contributed to the annual value of -$200,831 for FY2024, which is 127.82% down from last year.
  • Latest data reveals that Immuneering reported Change in Accured Expenses of $380,304 as of Q4 2024, which was down 54.49% from $835,677 recorded in Q3 2024.
  • Immuneering's Change in Accured Expenses' 5-year high stood at $2.1 million during Q3 2022, with a 5-year trough of -$2.8 million in Q1 2024.
  • In the last 3 years, Immuneering's Change in Accured Expenses had a median value of $444,094 in 2022 and averaged $82,977.
  • Per our database at Business Quant, Immuneering's Change in Accured Expenses tumbled by 465.33% in 2022 and then soared by 6,883.87% in 2024.
  • Over the past 5 years, Immuneering's Change in Accured Expenses (Quarterly) stood at -$257,046 in 2020, then surged by 314.39% to $551,080 in 2021, then tumbled by 83.84% to $89,032 in 2022, then spiked by 2,085.96% to $1.9 million in 2023, then plummeted by 80.46% to $380,304 in 2024.
  • Its Change in Accured Expenses stands at $380,304 for Q4 2024, versus $835,677 for Q3 2024 and $1.3 million for Q2 2024.